Sonoma Pharmaceuticals Inc. witnessed a substantial increase in its stock value during Thursday's extended trading hours, with shares climbing over 16%. This surge is attributed to the company's recent introduction of a burn relief hydrogel into prominent retail chains, indicating a strategic expansion into the consumer market for its hypochlorous acid-based skincare solutions.
The company, trading under the NASDAQ ticker SNOA, observed its stock price reach $2.44 after the close of regular trading, which marked a recovery from a 7.89% dip earlier in the day. This rebound highlights investor optimism regarding Sonoma's latest venture into the over-the-counter burn care segment, building upon its established success in professional healthcare.
Sonoma's new hydrogel, designed for minor burns and skin irritations, is now available in Walmart and CVS stores across the United States. This broad distribution is facilitated through a key domestic partner, signifying a major milestone for SNOA as it broadens its product accessibility to a wider consumer base. CEO Amy Trombly emphasized the growing public recognition of hypochlorous acid (HOCl) as a safe and effective component in skincare, which underpins the strategic timing of this launch.
This retail expansion is a natural progression for Sonoma Pharmaceuticals, which has a solid track record in wound and burn care within professional medical settings. The company had previously ventured into mass retail in 2025 with a diaper rash hydrogel, demonstrating a consistent strategy of leveraging its expertise in specialized care to enter broader consumer markets. The successful launch of previous products and the current burn relief hydrogel underscore Sonoma's commitment to innovation and market growth.
Financially, Sonoma Pharmaceuticals recently reported a third-quarter revenue of $4.35 million, slightly exceeding analyst expectations. Despite a 27.08% decline in the stock over the past year, the company's market capitalization stands at $3.63 million, with its stock currently trading near its annual low. The Relative Strength Index (RSI) for SNOA is noted at 29.16, and recent trading metrics suggest a negative price trend across various timeframes, as per Benzinga's Edge Stock Rankings. However, the latest product launch and subsequent after-hours rally could signal a potential shift in investor sentiment and market performance.
This latest development from Sonoma Pharmaceuticals not only signifies an expansion in its product line but also reinforces its position in the competitive over-the-counter healthcare market. By making its innovative HOCl-based solutions more accessible, the company aims to capitalize on increasing consumer demand for effective and safe skincare options, potentially paving the way for future growth and market penetration. The move is expected to bolster the company's revenue streams and enhance its brand visibility among general consumers.